Joint Symposium 7
Neuroimaging Committee/ EANO
Tuesday, October 22, 15:00 - 16:30

Session Title
Advances in Meningioma Diagnosis and Therapy

Chairpersons
Nelleke Tollbom (Utrecht, Netherlands)
Antoine Verger (Nancy, France)

Programme

15:00 - 15:30 **Felix Sahm** (Heidelberg, Germany): Classification and molecular pathology of meningiomas

15:30 - 16:00 **Matthias Preusser** (Vienna, Austria): Treatment standards of meningiomas - current standard and future avenues

16:00 - 16:30 **Nathalie Albert** (Munich, Germany): Theranostics in meningiomas - from rationale to evidence

Educational Objectives
1. To learn about the role of molecular pathology for the classification of meningioma
2. To get an overview of treatment standards and novel therapeutic approaches
3. To understand the current level of evidence for the efficacy of SSR-directed radionuclide therapy in meningioma

Summary
Meningiomas are the most common primary intracranial tumors in adults with increasing incidence. While most meningiomas are considered to exhibit non-malignant behaviour, a subset is characterized by biologically aggressive behaviour and poor outcome. Advances in molecular testing and correlation with outcome measures have led to the incorporation of molecular biomarkers into meningioma grading and prognostication. This EANM / EANO joint symposium will provide an overview on recent advances in molecular pathology and meningioma classification, on current treatment standards during the course of the disease and give an outlook on upcoming treatment strategies. In this context, the high potential of SSR-directed radionuclide therapy will be discussed with a particular focus on the current level of evidence, the opportunities and shortcomings of off-label use and compassionate use programs, and give an outlook on the upcoming first randomized prospective trial with [^{177}Lu]Lu-DOTATATE in patients with recurrent meningioma.

Key Words
Meningioma; molecular classification; targeted therapies; radionuclide therapy; PRRT